Testing nursing homes for COVID-19 costs $440M

Testing all residents and staff at the nation’s nursing homes just once would collectively cost $440 million, according to data from the American Health Care Association and National Center of Assisted Living (AHCA/NCAL).

The findings underscore just how expensive COVID-19 testing can be, with nursing homes asking for more federal aid to respond. The total cost does not include testing for other long-term care facilities including assisted living.

The CDC recently recommended nursing homes to increase COVID-19 testing, but the cost of testing all residents and staff would come to more than $1 billion per month. According to AHCA/NCAL, the cost of testing is “unsustainable.”

“For months now, we have been advocating for expanded and priority testing in nursing homes to protect our residents and caregivers, but this is a significant undertaking and cost for nursing homes to shoulder on their own,” Mark Parkinson, president and CEO of American Health Care Association and National Center of Assisted Living, said in a statement. “That’s why we have asked HHS to grant our request for a $10 billion emergency relief to help fund expedited testing and the additional staffing needed to respond to this unprecedented health crisis.” 

Nursing homes are some of the most vulnerable facilities to COVID-19, which can cause serious illness and death in.

Broken down by state, California would see the highest cost of testing every resident and staff one time, coming it at $36,381,000, according to the report. The cost for New York is estimated at $33,955,950, while the cost for Texas would be $29,001,150. By comparison, testing all residents and staff would cost Wyoming just $658,350.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.